Foundation Medicine to Present Clinical Data on its FoundationOne™ Cancer Genomic Profile at the 2013 ASCO Annual Meeting

<0> Pure Communications, Inc.Dan Budwick, 973-271-6085 </0>

, a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced that 12 abstracts highlighting the company’s progress in clinical cancer genome sequencing will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago.

“As clinical adoption of our solid tumor assay, FoundationOne™, continues to increase, we are generating a large body of evidence suggesting that a comprehensive genomic profile may provide clinically actionable information for many patients with cancer,” said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. “These data include novel findings across many tumor types and for many genomic targets. The 2013 ASCO meeting will be an exciting venue to share and discuss new discoveries in cancer genomics with the broader oncology community.”

The schedule for presentations by Foundation Medicine and/or its collaborators is as follows:

Saturday,June 1, 2013 from 8:00 a.m. – 12:00 p.m. CTFrequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS) 534Poster Discussion Session: Breast Cancer – HER2/ERE450bMark J. Ratain, M.D.

Saturday,June 1, 2013 from 8:00 a.m. – 12:00 p.m. CTInflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions 10513Poster Discussion Session: SarcomaS102Christine M. Lovly, M.D., Ph.D.

Saturday, June 1, 2013 from 1:15 – 5:00 p.m. CTNext generation sequencing (NGS) in patients with advanced metastatic breast cancer: identification of molecular alterations and analysis of associations with treatment on Phase I studies at MD Anderson Cancer Center 1051General Poster Session: Breast Cancer – Triple-Negative/Cytotoxics/Local TherapyS Hall A2Jennifer J. Wheler, M.D.

Saturday, June 1, 2013 from 1:15 – 5:00 p.m. CTTargeted next-generation sequencing of sarcomas for identification of therapeutic targets 10577General Poster Session: SarcomaS Hall A2Vinod Ravi, M.D.

Saturday,June 1, 2013 from 2:00 – 2:15 p.m. CTNext generation sequencing of genomic and cDNA identifies a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors 9002Oral Abstract Session: Melanoma/Skin Cancers5406 Boris Bastian, M.D., Ph.D., University of California, San Francisco

Sunday, June 2, 2013 from 8:00 – 8:15 a.m. CTAn analysis of alterations (amplifications and mutations) found by next generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients 11000Oral Abstract Session: Tumor BiologyE354b Massimo Cristofanilli, M.D., F.A.C.P., Thomas Jefferson University-Kimmel Cancer Center

Sunday, June 2, 2013 from 8:00 a.m. – 12:00 p.m. CTClinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients 8020Poster Discussion Session: Lung Cancer – Non-small Cell MetastaticE450bSiraj M. Ali, M.D., Ph.D.

Sunday,June 2, 2013 from 8:00 a.m. – 12:00 p.m. CTNTRK1 gene fusions represent a novel oncogene target in lung cancer 8023Poster Discussion SessionE450bRobert C. Doebele, M.D., Ph.D.

MondayJune 3, 2013 from 8:00 a.m. – 12:00 p.m. CTUse of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples 11020Poster Discussion Session: Tumor BiologyS102Vincent A. Miller, M.D.

Monday, June 3, 2013 from 1:15 – 5:15 p.m. CTUse of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer 1009Poster Discussion Session: Breast Cancer – Triple-Negative/Cytotoxics/Local TherapyS102Jeffrey S. Ross, M.D.

Monday, June 3, 2013 from 1:15 – 5:00 p.m. CTClinical next generation sequencing (NGS) of fine needle aspiration (FNA) biopsies in non-small cell lung (NSCLC) and pancreatic cancers 11100General Poster Session: Tumor BiologyS Hall A2Matthew J. Hawryluk, Ph.D.

Monday, June 3, 2013 from 1:15 – 5:00 p.m. CTFrequency of MET amplification determined by comprehensive next generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors 11068General Poster Session: Tumor BiologyS Hall A2Norma A. Palma, Ph.D.

is a fully informative genomic profile that complements traditional cancer decision tools and often expands treatment options by matching each patient with targeted therapies that may be relevant to the molecular changes in their tumor. Using next-generation sequencing, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. Each patient’s genomic profile is reported to the physician matched with targeted therapies and clinical trials that may be relevant based on the molecular blueprint of their tumor. Results are supported by the latest scientific and medical evidence. FoundationOne has been optimized to fit easily into the clinical workflow of a practicing oncologist. It is available for all solid tumors and clinical grade results can be obtained from as little as 50ng of DNA obtained from formalin-fixed, paraffin-embedded tumor tissue samples. FoundationOne is a laboratory-developed test performed at Foundation Medicine’s CLIA-certified facility and is currently available for all solid tumor types. Please visit www.FoundationOne.com for more information.

is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical assay, , is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit or follow Foundation Medicine on (@FoundationATCG).

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.